Patents Issued in August 28, 2014
  • TRANSGENIC THERAPEUTIC STEM CELLS AND METHODS FOR THEIR USE AND MANUFACTURE
    Publication number: 20140242047
    Abstract: The invention relates to transgenic stem cells for therapeutic use. Stem cells according to the invention comprise at least one therapeutic trans gene that is expressed when transplanted to a subject. Methods of use and manufacturing the transgenic stem cells of the invention are also contemplated, including the use of transiently transgenic G-CSF bone marrow stem cells for treating the penumbra of ischemic tissues such as central nervous system tissues.
    Type: Application
    Filed: February 25, 2013
    Publication date: August 28, 2014
    Inventors: ALEX KHARAZI, MG MURALIDHAR, GRIGORY VERELOV
  • Methods For Controlling Pests
    Publication number: 20140242048
    Abstract: Involved is a method for controlling the pest Sesamia inferens, comprising the step of contacting Sesamia inferens with Cry1B protein. Sesamia inferens is controlled by the Cry1B protein having pesticidal activity against Sesamia inferens, which is produced in the plants. Compared with the agricultural control, chemical control and biology control currently used in prior art, the present application can protect the whole plant during whole growth period from the harm of Sesamia inferen. Furthermore, it causes no pollution and no residue and provides a stable and thorough control effect. Also it is simple, convenient and economic.
    Type: Application
    Filed: January 21, 2014
    Publication date: August 28, 2014
    Applicants: Beijing Dabeinong Technology Group Co., Ltd., Beijing Green Agrosino Plant Protection Technology Co., Ltd., Beijing Dabeinong Technology Group Co., Ltd., Biotech Center
    Inventors: Derong DING, Jie PANG, Chao HAN
  • MUTANT CTLA4 GENE TRANSFECTED T CELL AND COMPOSITION INCLUDING SAME FOR ANTICANCER IMMUNOTHERAPY
    Publication number: 20140242049
    Abstract: A transformed T-cell for T-cell therapy, and a composition including the same for anticancer immunotherapy. More particularly, the transformed T-cell is characterized by the transfection of a gene for coding a chimera protein. The T-cell, to which the gene for coding the chimera protein is transected, may improve the therapeutic effects induced by immune tolerance of cancer cells, and furthermore maximize anti-cancer effects by activating signal transduction to induce the activation of T-cells. Also, the disclosure allows treatments that minimize side effects such as the development of autoimmune diseases due to systematic T-cell activation.
    Type: Application
    Filed: October 26, 2012
    Publication date: August 28, 2014
    Applicant: NATIONAL CANCER CENTER
    Inventors: Kyungho Choi, Jaehun Shin, Sang-Jin Lee
  • NUTRITIONAL COMPOSITION COMPRISING PROBIOTICS AND IMPROVING SLEEP PATTERNS
    Publication number: 20140242050
    Abstract: This invention relates to the use of a probiotic bacterial strain in the manufacture of a medicament or therapeutic nutritional composition for improving the maturation of sleep patterns in infants, young children or young animals and/or for reducing sleep disturbances and/or improving sleep patterns in humans or animals at any age.
    Type: Application
    Filed: March 5, 2014
    Publication date: August 28, 2014
    Applicant: NESTEC S.A.
    Inventors: Gabriela Bergonzelli Degonda, Isabelle Bureau-Franz, Clara Lucia Garcia-Rodenas
  • Probiotic, Lactic Acid-Producing Bacteria and Uses Thereof
    Publication number: 20140242051
    Abstract: The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 28, 2014
    Applicant: GANEDEN BIOTECH, INCORPORATED
    Inventor: Sean Farmer
  • TREATMENT AND/OR PROPHYLAXIS OF STORAGE DISEASES OF HARVESTED MATERIAL
    Publication number: 20140242052
    Abstract: The present invention relates to the treatment and/or prophylaxis of storage diseases of harvested material.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 28, 2014
    Applicant: SOURCON-PADENA GmbH & CO.KG.
    Inventor: Wolfgang Vogt
  • METHOD FOR USING DIRECTING CELLS FOR SPECIFIC STEM/PROGENITOR CELL ACTIVATION AND DIFFERENTIATION
    Publication number: 20140242053
    Abstract: A method is provided, including obtaining a population of antigen-presenting cells, enriching a population of stem/progenitor cells within a larger population of cells, activating the population of antigen-presenting cells and, following the activating, inducing at least one process selected from the group consisting of: differentiation, expansion, activation, secretion of a molecule, and expression of a marker, by exposing the enriched stem/progenitor cell population to the population of antigen-presenting cells. Other applications are also described.
    Type: Application
    Filed: March 11, 2014
    Publication date: August 28, 2014
    Applicant: BIOGENCELL, LTD
    Inventor: Yael Porat
  • METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY CONDITIONS USING PLATELET ENRICHED PLASMA
    Publication number: 20140242054
    Abstract: Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in particular, equines, by administration to the respiratory system.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 28, 2014
    Applicant: VETGEL TECHNOLOGIES
    Inventor: Richard Gold
  • COMPOSITIONS CONTAINING NON-POLAR COMPOUNDS
    Publication number: 20140242055
    Abstract: Provided herein are compositions and methods for preparing foods and beverages that contain additives, such as nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Inventor: Philip J. Bromley
  • PREPARATION OF STABILIZED CATALASE ENZYMES USING POLYVINYL ALCOHOL
    Publication number: 20140242056
    Abstract: There is provided a method of producing a stabilized catalase enzyme. In the method, a substrate is thoroughly mixed with phosphate borate and catalase, rinsed with water and the solids dried. The dried solid may be mixed with polyvinyl alcohol and dried for further stabilization. The stabilized powder may be mixed with various skin solutions (lotions, ointments and the like). The catalase enzyme can catalyze the reaction of peroxide to oxygen.
    Type: Application
    Filed: February 21, 2014
    Publication date: August 28, 2014
    Applicant: Kimberly-Clark Worldwide, Inc.
    Inventors: Bhalchandra M. Karandikar, Sunita J. Macwana, Zhongju Liu Zhao
  • CONJUGATED FACTOR VIII MOLECULES
    Publication number: 20140242057
    Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: Novo Nordisk A/S
    Inventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
  • ST6GAL I MEDIATED MODULATION OF HEMATOPOIESIS
    Publication number: 20140242058
    Abstract: Provided are methods for reducing haematocytes in an individual. The method involve administering to an individual a composition that contains recombinant a2,6-sialyltransferase (ST6Gal I). The method is suitable for prophylaxis and therapy of a condition that is positively correlated with undesirable hematopoiesis. Such conditions include autoimmune diseases, transplantation rejection, blood cancers and allergic reactions and inflammations. The invention also provides a pharmaceutical preparation that contains recombinant ST6Gal I and which is suitable for administration to an individual to reduce haematocytes in the individual, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: June 25, 2012
    Publication date: August 28, 2014
    Applicant: Health Research, Inc.
    Inventors: Joseph Lau, Mehrab Nasiri Kenari
  • COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF
    Publication number: 20140242059
    Abstract: Disclosed is a composition comprising recombinant iduronate-2-sulfatase (IDS). The glycosylation pattern and formylglycine content of the IDS composition are different from those of Elaprase and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Application
    Filed: June 15, 2012
    Publication date: August 28, 2014
    Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATION
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • COMPOSITIONS OF ENGINEERED HUMAN ARGINASES AND METHODS FOR TREATING CANCER
    Publication number: 20140242060
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Application
    Filed: May 12, 2014
    Publication date: August 28, 2014
    Applicant: AERASE, INC.
    Inventors: George GEORGIOU, Everett STONE
  • COMPOSITIONS AND METHODS FOR TREATING GAUCHER DISEASE
    Publication number: 20140242061
    Abstract: Methods and compositions for treating Gaucher disease are described.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 28, 2014
    Applicant: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Peter Francis Daniel, Michael W. Heartlein
  • MODIFIED PROTEASES THAT INHIBIT COMPLEMENT ACTIVATION
    Publication number: 20140242062
    Abstract: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders.
    Type: Application
    Filed: May 12, 2014
    Publication date: August 28, 2014
    Applicant: Catalyst Biosciences, Inc.
    Inventors: Edwin L. Madison, Jack Nguyen, Sandra Waugh Ruggles, Christopher Thanos
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20140242063
    Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.
    Type: Application
    Filed: October 10, 2013
    Publication date: August 28, 2014
    Applicant: VALEANT LABORATORIES INTERNATIONAL BERMUDA
    Inventors: Andrew John DUFFIELD, Graham JACKSON, Steven E. FRISBEE
  • METHODS AND APPARATUS FOR DELIVERING A THERAPEUTIC AGENT TO NASOPHARYNGEAL MUCOSA TARGETS
    Publication number: 20140242064
    Abstract: A system for delivering a therapeutic agent to a nasopharyngeal mucosa target comprises a foam generating mechanism, a gas, a therapeutic agent in liquid form that inhibits mucus production, and a delivery device. Actuation of the foam generating mechanism entraps gaseous bubbles from the gas in the liquid thereby forming a foam. The therapeutic agent is dispersed in the foam which has an expanded configuration adapted to fill a nasopharyngeal space and deliver the therapeutic agent to the mucosa targets. The delivery device is for delivering the foam to the nasopharyngeal space. The foam may also have a collapsed configuration for removal from the nasopharyngeal space or for concentration of the therapeutic agent onto the mucosa.
    Type: Application
    Filed: January 9, 2014
    Publication date: August 28, 2014
    Applicant: The Foundry, LLC
    Inventors: John Morriss, Cary Reich, Hanson Gifford
  • Compositions for Regenerating Defective or Absent Myocardium
    Publication number: 20140242065
    Abstract: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
    Type: Application
    Filed: May 5, 2014
    Publication date: August 28, 2014
    Inventor: Robert G Matheny
  • FORMULATION AND TREATMENT FOR ACNE
    Publication number: 20140242066
    Abstract: The present invention relates to composition comprising Lactobacillus rye ferment, dialkylisosorbide and phospholipid. Preferably, the composition further comprises ethoxylated sorbitan fatty acid ester. The composition has been shown to be effective against infections of closed comedones. The invention further relates to a method of preparing the composition, to a roll-on applicator comprising the composition and to the use of the composition in treatment of closed comedones infections.
    Type: Application
    Filed: September 20, 2012
    Publication date: August 28, 2014
    Inventor: Elzbieta Ewa Brand-Garnys
  • TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY INTRANASAL ADMINISTRATION OF IMMUNOGLOBULIN G
    Publication number: 20140242067
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Application
    Filed: February 25, 2014
    Publication date: August 28, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
  • JAML SPECIFIC BINDING AGENTS, ANTIBODIES, AND USES RELATED THERETO
    Publication number: 20140242068
    Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
    Type: Application
    Filed: August 10, 2012
    Publication date: August 28, 2014
    Applicant: EMORY UNIVERSITY
    Inventors: Charles A. Parkos, Dominique A. Weber
  • KRT19 Stabilizing HER2 and Use thereof
    Publication number: 20140242069
    Abstract: Provided is a method of decreasing the stability of HER2 (human epidermal growth factor receptor 2) in a cell or individual comprising administering an effective amount of an expression or activity inhibitor of KRT19 (cytokeratin 19) to the cell or individual.
    Type: Application
    Filed: February 26, 2013
    Publication date: August 28, 2014
    Inventors: In-Cheol Shin, Tae-Hoon Lee, Ji-Hyun JU, Kyung-Min Lee, Won-Seok Yang
  • FRIZZLED 2 AS A TARGET FOR THERAPEUTIC ANTIBODIES IN THE TREATMENT OF CANCER
    Publication number: 20140242070
    Abstract: Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates Fzd2. The antibody may specifically bind Fzd2, and may promote internalization of the Fzd2 receptor by the cancer cells and/or prevent ligand binding to Fzd2. Specific antibodies, and also specific portions of the Fzd2 molecule for antibody binding are disclosed. In one embodiment the antibody specifically binds to the epitope HGAEQICVGQNHSEDGAPAL (SEQ ID NO: 1). Specific cancers (e.g. late stage hepatocellular carcinoma), intended for treatment are provided, and include cancers that exhibit overexpression of Fzd2, and/or Wnt5a.
    Type: Application
    Filed: June 15, 2012
    Publication date: August 28, 2014
    Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Taranjit S. Gujral, Gavin MacBeath
  • M-CSF SPECIFIC MONOCLONAL ANTIBODY AND USES THEREOF
    Publication number: 20140242071
    Abstract: M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
    Type: Application
    Filed: February 3, 2014
    Publication date: August 28, 2014
    Applicants: XOMA TECHNOLOGY LTD., NOVARTIS VACCINES AND DIAGNOSTICS INC.
    Inventors: Cheng Liu, Deborah Lee Zimmerman, Gregory Martin Harrowe, Kirston Koths, William M. Kavanaugh, Li Long, Maria Calderon-Cacia, Arnold Horwitz
  • ANTI-ICAM-1 ANTIBODIES TO TREAT MULTIPLE-MYELOMA RELATED DISORDERS
    Publication number: 20140242072
    Abstract: The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 28, 2014
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventor: Markus Hansson
  • CARTILAGE/BONE DESTRUCTION SUPPRESSOR
    Publication number: 20140242073
    Abstract: An object of the present invention is to provide a cartilage/bone destruction suppressor which can suppress the destruction of cartilage or bone seen in rheumatoid arthritis, osteoarthritis, bone metastasis of malignant tumor, or the like. The present invention relates to a cartilage or bone destruction suppressor comprising an antibody against folate receptor ? or a complex of the antibody and a biologically or chemically active substance.
    Type: Application
    Filed: August 10, 2012
    Publication date: August 28, 2014
    Applicant: KAGOSHIMA UNIVERSITY
    Inventors: Takami Matsuyama, Taku Nagai
  • MATERIALS AND METHODS FOR MODULATING ACTIVITY OF BONE MARROW DERIVED CELLS
    Publication number: 20140242074
    Abstract: The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating 5 conditions amenable to treatment by recruitment of bone marrow-derived cells, such as BMDEC and bone marrow-derived angio-osteogcnic progenitor cell.
    Type: Application
    Filed: August 30, 2012
    Publication date: August 28, 2014
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Kirk P. Conrad, Mark S. Segal
  • ANTIBODY VARIANTS AND USES THEREOF
    Publication number: 20140242075
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Application
    Filed: July 6, 2012
    Publication date: August 28, 2014
    Applicant: GENMAB B.V.
    Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
  • MULTISPECIFIC MUTATED ANTIBODY FAB FRAGMENTS
    Publication number: 20140242076
    Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having mutations at the interface of the CH1 and CL domains, said mutations preventing heavy/light chain mispairing.
    Type: Application
    Filed: July 6, 2012
    Publication date: August 28, 2014
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE LAUSANNE, AZIENDA OSPEDALIERA PARA GIOVANNI XXIII
    Inventors: Jean Kadouche, Jean-Pierre Mach, Olivier Michielin, Vincent Zoete, Justyna Iwaszkiewicz, Martine Cerutti, Sylvie Choblet, Josee Golay
  • METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE
    Publication number: 20140242077
    Abstract: Provided are multispecific binding proteins and methods for using these multispecific binding proteins to modulate the activation state of immune cells, such as T-cells (e.g., cytotoxic T-cells). Also provided are methods of modulating an immune response (e.g., cell killing by cytotoxic T-cells) in a subject (e.g., a human subject). Also provided are nucleic acids, expression vectors and host cells encoding the multispecific binding proteins.
    Type: Application
    Filed: January 23, 2014
    Publication date: August 28, 2014
    Applicant: AbbVie, Inc.
    Inventors: Chee-Ho CHOI, Qingfeng TAO, Philip BARDWELL, Tariq GHAYUR
  • METHODS AND MONITORING OF TREATMENT WITH A WNT PATHWAY INHIBITOR
    Publication number: 20140242078
    Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.
    Type: Application
    Filed: February 3, 2014
    Publication date: August 28, 2014
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Jakob DUPONT, Robert J. STAGG
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20140242079
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 24, 2014
    Publication date: August 28, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Marina Bacac, Thomas Hofer, Ralf Hosse, Christiane Jaeger, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
    Publication number: 20140242080
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 24, 2014
    Publication date: August 28, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Christiane Jaeger, Christian Klein, Ekkehard Moessner, Pablo Umana
  • DOSING REGIMENS FOR TREATMENT OF CEA-EXPRESSING CANCERS
    Publication number: 20140242081
    Abstract: The present disclosure provides compositions and methods for treating CEA-expressing cancers. Methods for dosing a patient with an antibody that binds to CEA and human CD3 are also provided.
    Type: Application
    Filed: July 18, 2011
    Publication date: August 28, 2014
    Applicants: MICROMET AG, MEDIMMUNE, LLC
    Inventors: Scott Hammond, Patricia Ryan, Song Ren, Petra Lutterbuese, Maria Amann
  • COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS
    Publication number: 20140242082
    Abstract: The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder.
    Type: Application
    Filed: February 21, 2014
    Publication date: August 28, 2014
    Applicant: Ophthotech Corporation
    Inventors: David Shima, Perry Calias, Anthony P. Adamis
  • ANTI-MCSP ANTIBODIES
    Publication number: 20140242083
    Abstract: The invention provides anti-MCSP antibodies and methods of using the same.
    Type: Application
    Filed: February 24, 2014
    Publication date: August 28, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Thomas Hofer, Ralf Hosse, Ekkehard Moessner
  • Angiopoietin-Like 4 and Its Use in Modulating Cell Leakiness
    Publication number: 20140242084
    Abstract: Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesive proteins on endothelial cells facilitates metastasis. The role of tumor secreted angiopoietin-like 4 (cANGPTL4) in vascular leakiness and metastasis is controversial due to the lack of understanding of how cANGPTL4 modulates vascular integrity. Here, we show that cANGPTL4 instigated the disruption of endothelial continuity by directly interacting with three novel binding partners, integrin ?5?1, VEcadherin and claudin-5, in a temporally sequential manner, thus facilitating metastasis. We showed that cANGPTL4 binds and activates integrin ?5?1-mediated Rac1/PAK signaling to weaken cell-cell contacts. cANGPTL4 subsequently associated with and declustered VE-cadherin and claudin-5, leading to endothelial disruption. Interfering with the formation of these cANGPTL4 complexes delayed vascular disruption.
    Type: Application
    Filed: August 8, 2012
    Publication date: August 28, 2014
    Applicant: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventor: Nguan Soon Tan
  • METHODS AND COMPOSITION FOR TESTING, PREVENTING, AND TREATING ASPERGILLUS FUMIGATUS INFECTION
    Publication number: 20140242085
    Abstract: As a result of the analysis by an SST-REX method so as to identify a target molecule for treating and testing an Aspergillus fumigatus infection, a YMAF1 protein has been found out, which is mainly localized in the cell wall of Aspergillus fumigatus. Moreover, it has been found out that YMAF1 protein-deficient Aspergillus fumigatus has reduced spore-forming ability and pathogenicity. Further, it has been found out that the survival rate of experimental mice having aspergillosis (invasive Aspergillus model mice) is improved by preparing and administering an antibody against the YMAF1 protein. Furthermore, it has been found out that Aspergillus fumigatus can be detected with a favorable sensitivity by an ELISA system using the antibody.
    Type: Application
    Filed: August 12, 2011
    Publication date: August 28, 2014
    Applicants: MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., NATIONAL INSTITUTE OF INFECTIOUS DISEASES
    Inventors: Yoshitsugu Miyazaki, Satoshi Yamagoe, Masunori Kajikawa, Masahito Sugiura, Reiko Itoh, Hirotaka Kumagai
  • POLYNUCLEOTIDES ENCODING SIGNAL PEPTIDE-CONTAINING MOLECULES
    Publication number: 20140242086
    Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.
    Type: Application
    Filed: April 8, 2014
    Publication date: August 28, 2014
    Applicant: Incyte Corporation
    Inventors: Preeti G. Lal, Y. Tom Tang, Gina A. Gorgone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice K. Au-Young, Henry Yue, Chandra S. Arvizu, Roopa M. Reddy, Jennifer L. Jackson, Olga Bandman
  • Modulation Of The VPS10p-Domain Receptor Family For The Treatment Of Mental And Behavioural Disorders
    Publication number: 20140242087
    Abstract: The present invention relates to methods for modulating the activity of one or more Vps10p-domain receptors selected from the group consisting of Sortilin, SorLA, SorCS1, SorCS2 and SorCS3, in an animal and methods for preparation of a medicament for the treatment of mental and behavioral disorders. The modulation is carried out by inhibiting or promoting the binding of ligands to the Vps10p-domain receptor. In vitro and in vivo methods for screening for agents capable of modulation of said Vps10p-domain receptor activity are also provided. The invention furthermore relates to methods of altering expression of said receptors in vivo.
    Type: Application
    Filed: February 27, 2014
    Publication date: August 28, 2014
    Applicant: H. LUNDBECK A/S
    Inventors: Simon Glerup Pedersen, Ulrich Bolcho, Kimmo Jensen, Anders Nykjaer
  • Hsp90 inhibitor combinations
    Publication number: 20140242088
    Abstract: A pharmaceutical combination comprising an Hsp90 inhibitor and an mTOR inhibitor, and methods of using the combination to treat or prevent proliferative disorders.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 28, 2014
    Applicant: Novartis AG
    Inventors: Carlos Garcia-Echeverria, Michael Rugaard Jensen
  • GLYCOPROTEINS HAVING LIPID MOBILISING PROPERTIES AND THERAPEUTIC APPLICATIONS THEREOF
    Publication number: 20140242089
    Abstract: A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-?2-glycoprotein, or of a fragment thereof having an apparent molecular mass Mr greater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material are also disclosed together with uses of the material for making up pharmaceutical compositions, especially pharmaceutical compositions useful for treating mammals to achieve weight reduction or for controlling obesity. In addition, uses of the material for developing diagnostic agents and for identifying inhibitors of lipolytic activity for therapeutic purposes are disclosed.
    Type: Application
    Filed: May 13, 2014
    Publication date: August 28, 2014
    Inventors: Michael J. Tisdale, Penio T. Totorov
  • METHODS FOR THE TREATMENT OF IL-1BETA RELATED CONDITIONS
    Publication number: 20140242090
    Abstract: Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies or binding fragment thereof).
    Type: Application
    Filed: September 17, 2013
    Publication date: August 28, 2014
    Applicant: XOMA Technology Ltd.
    Inventors: Alan M. Solinger, Ahmet Gül
  • METHOD FOR TREATING PATHOLOGIES ASSOCIATED WITH HYPOXIA USING MIF INHIBITORS
    Publication number: 20140242091
    Abstract: Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for reating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided.
    Type: Application
    Filed: May 13, 2014
    Publication date: August 28, 2014
    Applicant: The Feinstein Institute For Medical Research
    Inventors: Edmund Miller, Yousef Al-Abed, Yinzhong Zhang, Kai Fan Cheng
  • VHZ FOR DIAGNOSIS AND TREATMENT OF CANCER
    Publication number: 20140242092
    Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.
    Type: Application
    Filed: May 13, 2014
    Publication date: August 28, 2014
    Applicant: Agency For Science, Technology And Research (A*STAR)
    Inventor: Qi Zeng
  • METHODS AND COMPOSITIONS FOR MODULATING THE INNATE IMMUNE RESPONSE AND/OR MYOGENESIS IN A MAMMALIAN SUBJECT
    Publication number: 20140242093
    Abstract: In one aspect, the present invention relates to methods for increasing, decreasing or maintaining the innate immune response in a mammalian subject comprising modulating the expression of DUX4-fl, or modulating the expression of beta-defensin 3 (DEFB103). In another aspect, the present invention relates to methods for increasing, decreasing or maintaining myogenesis or muscle differentiation in a mammalian subject comprising modulating the expression of beta-defensin 3 (DEFB103). In additional aspects, the present invention involves diagnostic methods based on assessment of identified biomarkers.
    Type: Application
    Filed: July 27, 2012
    Publication date: August 28, 2014
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Stephen J. Tapscott, Linda Geng
  • METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS
    Publication number: 20140242094
    Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 28, 2014
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
  • ANTIBODIES AND ANTIBODY FRAGMENTS TARGETING SIRP-ALPHA AND THEIR USE IN TREATING HEMATOLOGIC CANCERS
    Publication number: 20140242095
    Abstract: The invention relates to modulating the SIRP?—CD47 interaction in order to treat hematological cancer and compounds therefor. In particular, there is also provided SIRP? antibodies and antibody fragments, preferably used for treating hematological cancer.
    Type: Application
    Filed: October 19, 2012
    Publication date: August 28, 2014
    Applicant: University Health Network
    Inventors: Jean C. Y. Wang, Jayne S. Danska, John Dick, Sachdev Sidhu, Maruti Uppalapati
  • COMPOSITIONS AND METHODS RELATED TO GRAFT VERSUS HOST DISEASE AND TREATMENTS THEREOF
    Publication number: 20140242096
    Abstract: Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha1-antitrypsin activities.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 28, 2014
    Applicant: The Regents of the University of Colorado, A Body Corporate
    Inventors: Shapiro Leland, Eli C. Lewis, Charles A. Dinarello